Effective cefiderocol CSF penetration for treating Stenotrophomonas maltophilia ventriculitis
JAC-Antimicrobial Resistance · 30.04.2026 · 8 (3)
DOI: 10.1093/jacamr/dlag092 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 02.06.2026. Verfasst von Clara Ribera und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Bacterial ventriculitis associated with CSF shunts or drains is a life-threatening infection often caused by MDR pathogens such as Stenotrophomonas maltophilia. Cefiderocol, an IV siderophore cephalosporin approved for drug-resistant Gram-negative infections, lacks extensive clinical data supporting its use in CNS infections.
Objectives
We describe a case of S. maltophilia ventriculitis successfully treated with cefiderocol monotherapy at a standard dose of 2 g IV every 8 h. Data on cefiderocol CSF drug penetration are reported.
Methods
Cefiderocol trough plasma and CSF concentrations (Cmin) were determined at steady-state conditions, and S. maltophilia susceptibility testing was determined using Etest and disc diffusion.
Results
Therapeutic drug monitoring showed sustained CSF cefiderocol concentrations. CSF cefiderocol Cmin remained 116.0- and 131.8-fold above the isolate’s MIC throughout the dosing interval, with plasma-to-CSF penetration ratios of 16.6%–25.7%. Patient’s clinical cure was achieved after 26 days of therapy without adverse events or relapse at 1 year of follow-up.
Conclusions
Our data show that cefiderocol at a standard dose of 2 g IV every 8 h achieved sustained therapeutic concentrations in the CSF. Cefiderocol monotherapy may be an option for CNS infections with MDR Gram-negative bacteria with low MICs such as S. maltophilia.
Autor:innen und Institutionen
- Pharmacy Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
- University of Barcelona, Faculty of Pharmacy, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Department of Clinical Microbiology, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
- Research Network for Respiratory Diseases (CIBERES-CB06/06/0037), Instituto de Salud Carlos III, Madrid, Spain.
- Intensive Care Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
ORCID-Profile: Jordi Càmara, Evelyn Shaw, Mireia Puig-Asensio
Zitieren
APA
Ribera, C., Padullés, A., Tubau, F., Corral, L., Nuñez Garate, M., Cabellos, C., Vilalta, A., Càmara, J., Cobo-Sacristán, S., Abelenda-Alonso, G., Di Paolo, F., Shaw, E., & Puig-Asensio, M. (2026). Effective cefiderocol CSF penetration for treating Stenotrophomonas maltophilia ventriculitis. JAC-Antimicrobial Resistance, 8(3). https://doi.org/10.1093/jacamr/dlag092
Vancouver
Ribera C, Padullés A, Tubau F, Corral L, Nuñez Garate M, Cabellos C, et al. Effective cefiderocol CSF penetration for treating Stenotrophomonas maltophilia ventriculitis. JAC-Antimicrobial Resistance. 2026;8(3). doi:10.1093/jacamr/dlag092
BibTeX
@article{Ribera2026,
author = {Ribera, Clara and Padullés, Ariadna and Tubau, Fe and Corral, Luisa and Nuñez Garate, Maria and Cabellos, Carmen and Vilalta, Alexandre and Càmara, Jordi and Cobo-Sacristán, Sara and Abelenda-Alonso, Gabriela and Di Paolo, Fabio and Shaw, Evelyn and Puig-Asensio, Mireia},
title = {Effective cefiderocol CSF penetration for treating Stenotrophomonas maltophilia ventriculitis},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {3},
doi = {10.1093/jacamr/dlag092}
}
EUVIMED